TABLE 1.
Patient characteristics.
| Characteristic | HRQoL, No. (%) | SAS/SDS, No. (%) |
|---|---|---|
| No. of patients | 146 (100.0) | 102 (100.0) |
| Age: Median [range], years | 42 [20–74] | 40 (20–64) |
| Men | 94 (64.4) | 66 (64.7) |
| Time from diagnosis to olverembatinib treatment: Median [range], years | 5.5 [0.4–23.2] | 5.9 [0.4–15.2] |
| Prior TKI | ||
| Imatinib | 19 (13.0) | 15 (14.7) |
| Imatinib/dasatinib | 54 (37.0) | 32 (31.4) |
| Imatinib/nilotinib | 25 (17.1) | 18 (17.6) |
| Imatinib/dasatinib/nilotinib | 36 (24.7) | 28 (27.5) |
| Nilotinib | 6 (4.1) | 5 (4.9) |
| Dasatinib | 2 (1.4) | 0 |
| Dasatinib/nilotinib | 4 (2.7) | 4 (3.9) |
| No. of lines of prior TKI therapy | ||
| 1 | 27 (18.5) | 20 (19.6) |
| 2 | 83 (56.8) | 54 (52.9) |
| ≥3 | 36 (24.7) | 28 (27.5) |
| BCR::ABL1 mutation status by Sanger sequencing | ||
| No mutation | 19 (13.0) | 19 (18.6) |
| T315I single mutation | 92 (63.0) | 55 (53.9) |
| T315I and other mutations | 22 (15.1) | 15 (14.7) |
| Other mutations | 13 (8.9) | 13 (12.7) |
| CML stage | ||
| CML‐CP | 114 (78.1) | 85 (83.3) |
| CML‐AP | 32 (21.9) | 17 (16.7) |
Abbreviations: CML, chronic myeloid leukemia; CML‐AP, chronic myeloid leukemia in accelerated phase; CML‐CP, chronic myeloid leukemia in chronic phase; HRQoL, health‐related quality of life; TKI, tyrosine kinase inhibitor.